{"product_id":"inpatient-dermatology-9783319184487","title":"Inpatient Dermatology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e​​​\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eInpatient Dermatology \u003c\/i\u003eis a concise and portable resource that synthesizes the most essential material to help physicians with recognition, differential diagnosis, work-up, and treatment of dermatologic issues in the hospitalized patient. \u003c\/p\u003e  \u003cp\u003eComplete with hundreds of clinical and pathologic images, this volume is both an inpatient dermatology atlas and a practical guide to day-one, initial work-up, and management plan for common and rare skin diseases that occur in the inpatient setting.\u003c\/p\u003e    \u003cp\u003eEach chapter is a bulleted, easy-to-read reference that focuses on one specific inpatient dermatologic condition, with carefully curated clinical photographs and corresponding histopathologic images to aid readers in developing clinical-pathologic correlation for the dermatologic diseases encountered in the hospital. Before each subsection the editors share diagnostic pearls, explaining their approach to these challenging conditions.\u003c\/p\u003e    This book is structured to be useful to physicians, residents, and medical students. It spans dermatology, emergency medicine, internal medicine, infectious disease, and rheumatology. \u003ci\u003eInpatient Dermatology\u003c\/i\u003e is the go-to guide for hospital-based skin diseases, making even the most complex inpatient dermatologic issues approachable and understandable for any clinician.\u003cp\u003e\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003ePreface\u003c\/b\u003e \u003cp\u003e\u003cb\u003ePart I: Introduction \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003eChapter 1. General Principles and Approach to Inpatient Dermatology\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003ein;mso-hansi-theme-font:major-latin;mso-bidi-font-family: \"Times New Roman\"\"\u0026gt;DIVIDER\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart II: Medication reactions\u003c\/b\u003e\u003cbr\u003e Chapter 2. Morbilliform drug eruption\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003eChapter 3. Urticaria\u003c\/p\u003e  ound-image: initial; Chapter 4. Stevens-Johnson Syndrome \/ Toxic Epidermal Necrolysis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 5. Erythema\u003c\/p\u003e Multiforme\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 6. Drug Hypersensitivity Syndrome\/Drug Rash with Eosinophilia and Systemic Symptoms \u003c\/p\u003e  \u003cp\u003eChapter 7. Acute Generalized Exanthematous Pustulosis \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003ept;line-height: 115.0%;Chapter 8. Fixed Drug Eruption\u003cp\u003e\u003c\/p\u003e  oNormal\"\u0026gt;Chapter 9. Serum Sickness-like Reaction \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eDIVIDER\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart III. Oncodermatology: Cancer- and treatment-related skin issues \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003euot;,\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-Chapter 10. Sweet Syndrome\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 11. Leukemia Cutis\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eily: Cambria , serif;\"\u0026gt;Chapter 12. Toxic Erythema of Chemotherapy\u003cp\u003e\u003c\/p\u003e  aChapter 13. Neutrophilic Eccrine Hidradenitis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 14. Transient acantholytic dermatosis\u003c\/p\u003epan style=\"font-size: 9pt; line-height: 115%; font-family: Cambria, serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"\u0026gt; of Chemotherapy\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eamily: Cambria , serif;\"\u0026gt;Chapter 15. \u003cp\u003e\u003c\/p\u003erepeat: initial; background-attachment: initial; background-origin: initial; background-clip: Serpentine Supravenous Hyperpigmentation\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 16. Epidermal Growth Fa\u003c\/p\u003ector Inhibitors\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 17. Bleomycin-induced flagellate erythema\u003c\/p\u003ebidi-font-family: \"Times New Roman\"\"\u0026gt;\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e9.0pt;line-Chapter 18. Graft-Versus-Host Disease: Acute  \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003ee: 9.0pt;line-heiChapter 19. Graft-Versus-Host Disease: Chronic \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eDIVIDER\u003c\/b\u003e\u003c\/p\u003et-size:9.0pt;line-height:115%; font-family:\"Cambria\",\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin\"\u0026gt;[KH1] \u003cb\u003e Infections and Infestations\u003c\/b\u003e\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart IV. Infections: Bacterial\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eine-height: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 20. Superficial Staphylococcal and Streptococcal Infections \u003cp\u003e\u003c\/p\u003e New Roman\";mso-bidi-theme-font:major-bidi; background:yellow;mso-highlight:yellow\"\u0026gt;\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 21. Cellulitis\u003c\/p\u003e  \u003cp\u003eChap\u003c\/p\u003eter 22. Necrotizing fasciitis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 23. Staphylococcal scalded skin syndrome \u003c\/p\u003est-font-family: \"Times New Roman\";mso-fareast-theme-font:major-fareast;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-bidi-theme-font:major-bidi; mso-ansi-lang\u003cp\u003e\u003c\/p\u003e  class=\"MsoNormal\"\u0026gt;Chapter 24. Echthyma Gangrenosum\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003emes New Roman\";mso-bidi-theme-font:major-bidi; mso-ansi-languageChapter 25. Purpura Fulminans\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 26. Meningococcal Infections\u003c\/p\u003e  \u003cp\u003eChapter 27. \u003c\/p\u003eyle=\"font-size: 9pt; line-height: 115%; font-family: Cambria, serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"\u0026gt;Atypical mycobacteria\u003cp\u003e\u003c\/p\u003e  al\"\u0026gt;\u003cp\u003e\u003c\/p\u003emes New Roman\";msoChapter 28. Lyme disease\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 29. Spotted Fever \u003c\/p\u003e  \u003cp\u003eChapter 30. Syphilis\u003c\/p\u003e  =\"MsoNormal\"\u0026gt;\u003cb\u003ePart V. Infections: Viral\u003c\/b\u003e\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 31. Herpes simplex virus \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eamily: Cambria , serif;\"\u0026gt;Chapter 32. Eczema Herpeticum\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003efont-size:9.0pt;line-height:115%; font-family:\"Cambria\",\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:Chapter 33. Varicella zoster virus\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 34. Coxsackie virus: Hand-Foot-Mouth Disease \u003c\/p\u003e  \u003cp\u003eChapter 35. \u003c\/p\u003e: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"\u0026gt;Human Immunodeficiency Virus \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003embria , serif;\"\u0026gt;Chapter 36. Kaposi’s Sarcoma \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e=\"FR\" style=\"font-size:9.0pt;line-height:115%;font-family:\"Cambria\",\"serif\"; mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-foPart VI. Infections: Fungal\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 37. Superficial Dermatophyte \/ Tinea \u003c\/p\u003e  \u003cp\u003eChapter 38. Candidiasis \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eine-height:115%; font-family:\"Cambria\",\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:FR\"\u0026gt;Chapter 39. Angioinvasive Fungal infections\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 40. Histoplas\u003c\/p\u003emosis\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 41. Coccidiodomycosis\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eot;Cambria\",\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"TimesChapter 42. Blastomycosis\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 43. Cryptococcosis\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart VII. Infections: Ectoparasitic Infestations\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eerif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:FR\"\u0026gt;Chapter 44. Scabies\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 45. Lice\u003c\/p\u003e  \u003cp\u003eChapter 46. Be\u003c\/p\u003ed Bugs \u003cp\u003e\u003c\/p\u003e\/p\u0026gt;  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003eeight:115%;font-family:\"Cambria\",\"serif\"; mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family: \"Times New Roman\";mso-ansi-language:FR\"\u0026gt;DIVIDER\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart VIII. Purpura: Vasculitis and Vasculopathy\u003c\/b\u003e\u003c\/p\u003ei-font-family:Arial;mso-ansi-language: FR\"\u0026gt;\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003et: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 47. Leukocytoclastic Vasculitis \/ Cutaneous small vessel vasculi\u003cp\u003e\u003c\/p\u003etis \u003cp\u003e\u003c\/p\u003e  \u0026gt;\u003cp\u003e\u003c\/p\u003epChapter 48. Granulomatosis with Polyangiitis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eme-font:major-latin; mso-bidi-font-family:\"Times New Roman\"Chapter 49. Eosinophilic Granulomatosis with Polyangiitis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 50. Microscopic Polyangiitis\u003c\/p\u003e New Roman\";mso-fareast-theme-font:major-fareast; mso-hansi-theme-font:major-latin;mso-bidi-font-family:\"Times New Roman\"; mso-bidi-theme-font:major-bidi\"\u0026gt;\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 51. \u003c\/p\u003eif;\"\u0026gt;Pol\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003eyarteritis Nodosa \u003cp\u003e\u003c\/p\u003e  soNormal\"\u0026gt;Chapter 52. Giant Cell Arteritis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 53. Cholesterol Emboli \u003c\/p\u003e  \u003cp\u003eChapter 54. \u003c\/p\u003erif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"\u0026gt;Infective Endocarditis\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e, serif;\"\u0026gt;Chapter 55. Cryoglobulinemia \u003cp\u003e\u003c\/p\u003e  \"\u0026gt;;\u003cp\u003e\u003c\/p\u003et: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:FRChapter 56. Antiphospholipid Antibody Syndrome \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 57. Calciphylaxis \u003c\/p\u003e  \u003cp\u003eChapter 58. \u003c\/p\u003erigin: initial; background-clip: initial;\"\u0026gt;Levamisole-Associat\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eDIVIDER\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart IX. Erythoderma\u003c\/b\u003e\u003c\/p\u003e  MsoNormal\"\u0026gt;t: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 59. \"\u0026gt;Medication-Induced Erythroderma \u003cp\u003e\u003c\/p\u003e  \"\u0026gt;\"font-size: 9.0pt;line-height: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 60. Atopic Dermatitis and Erythroderma \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003emajor-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:FR\"\u0026gt;Chapter 61. Psoriasis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 62. Cutaneous T-Cell Lymphoma \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 63. \u003c\/p\u003etial; background-origin: initial; background-clip: initial;\"\u0026gt;Pityriasis Rubra Pilaris \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003eR\" styDIVIDER\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e; mso-ascii-theme-font:major-latin;mso-hansi-theme-font:major-latin;mso-bidi-font-family: \"Times New Roman\";mso-ansi-language:FR\"\u0026gt;Part X. Inflammatory and Autoimmune Conditions\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e;\"\u0026gt; \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eidi-foChapter 64. Pyoderma Gangrenosum \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 65. Panniculitis \/ Erythema nodosum \u003c\/p\u003e  \u003cp\u003eChapter 66. Lichen Planus \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003euot;,\"serif\";mso-ascii-theme-font:major-latin;mso-hansi-theme-font: major-latin;mso-bidi-font-family:\"Times New Roman\";mso-ansi-language:FR\"\u0026gt;Chapter 67. Dermatomyositis \u003cp\u003e\u003c\/p\u003e  \"\u0026gt;=\"FR\" style=\"font-size: 9.0pt;line-height: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 68. Lupus \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eChapter 69. \u003cp\u003e\u003c\/p\u003ees New Roman\"\"\u0026gt;Bullous Pemphigoid \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 70. Pemphigus Foliaceus \u003c\/p\u003e  \u003cp\u003eChapter 71. Pemphigus Vulgaris \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eChapter 72. \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e Roman\";mso-bidi-theme-font:major-bidi\"\u0026gt;Chapter 73. Dermatitis Herpetiformis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eine-height: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 74. Systemic Sclerosis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eChap\u003cp\u003e\u003c\/p\u003eter 75. Systemic Amyloidosis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003edi-font-family:\"Times New Roman\"\"\u0026gt; \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eDIVIDER\u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003ePart XI: Hospital-Related Skin Problems\u003c\/b\u003e\u003c\/p\u003eTimes New Roman\"; mso-hansi-theme-font:major-latin;mso-bidi-font-family:Arial\"\u0026gt;\u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003estyle=\"font-size: 9.0pt;line-heigh \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e%;font-family: Cambria , serif;\"\u0026gt;Chapter 76. Stasis Dermatitis \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003et: 115.0%;font-family: Cambria , serif;\"\u0026gt;Chapter 77. Miliaria \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003eine-height:115%;font-family: \"Cambria\",\"serif\";mso-ascii-theme-fontChapter 78. Decubitus Ulcers\u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 79. Inte\u003c\/p\u003ertrigo \u003cp\u003e\u003c\/p\u003e  \u003cp\u003eChapter 80. Contact Dermatitis \u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003ei-font-family:\"Times New Roman\"\"\u0026gt;Chapter 81. Edema Blisters \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e\u003c\/p\u003eChapter 82. Steroid Acne\u003cp\u003e\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":53517124403543,"sku":"9783319184487","price":134.99,"currency_code":"GBP","in_stock":true}],"url":"https:\/\/bookcurl.com\/products\/inpatient-dermatology-9783319184487","provider":"Book Curl","version":"1.0","type":"link"}